The clinical impact of nephrotoxicity in liver transplantation

Transplantation

Volumn 69, Issue 12 SUPPL., 2000, Pages

  Fisher, Neil C ^a   Malag, Massimo ^a   Gonzlez Pinto, Ignacio ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; TACROLIMUS;

CONFERENCE PAPER; HEPATORENAL SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER TRANSPLANTATION; NEPHROTOXICITY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE;

EID: 0342656575     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200006271-00005     Document Type: Conference Paper

References (28)

1. Iwatsuki S, Starzl TE, Todd S, et al. Experience in 1000 liver transplants under cyclosporin-steroid therapy: a survival report. Transplantat Proc 1988; 20: 498-504.
2. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423-428.
3. McCauley J, Van Thiel DH, Starzl TE, Puschett JB. Acute and chronic renal failure in liver transplantation. Nephron 1990; 55(2): 121-128.
4. Rigg KM. Renal transplantation: current status, complications and prevention. J Antimicrob Chemother 1995; 36(suppl B): 51-57.
5. Trull AK, Best NG, Tan KK, et al. Blood cyclosporine concentrations but not doses correlate with acute changes in renal function following heart and heart-lung transplantation. Ther Drug Monit 1992; 14: 275-280.
6. Azoulay D, Lemoine A, Dennison A, et al. Incidence of adverse reactions to cyclosporine after liver transplantation is predicted by the first blood level. Hepatology 1993; 18: 1123-1126.
7. Olyaei AJ, de Mattos AM, Bennett WM. Immunosuppressant-induced nephropathy. Pathophysiology, incidence and management. Drug Saf 1999; 21: 471-488.
8. Hamilton GS, Steiner JP. Immunophilins: beyond immunosuppression. J Med Chem 1998; 41: 5119-5143.
9. Keating J, Neuberger J, Clarke M, et al. Renal function and morphology in cyclosporin A-treated liver transplant recipients. Clin Transplant 1988; 2: 110-116.
10. Palestine AG, Austin HA, Balow JE, et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 1986; 314: 1293-1298.
11. Mihatsch MJ, Kyo M, Morozumi K, et al. The side-effects of cyclosporine-A and tacrolimus. Clin Nephrol 1998; 49: 356-363.
12. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110-1115.
13. Platz K-P, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58: 170-178.
14. Falkenhain ME, Cosio FG, Sedmak DD. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996; 62: 364-370.
15. Rimola A, Galver JS, Schade RR, et al. Effects of renal impairment on liver transplantation. Gastroenterology 1987; 93: 148-156.
16. Monsour HP, Wood RP, Dyer CH, Galati JS, Ozaki CF, Clark JH. Renal insufficiency and hypertension as long-term complications in liver transplantation. Semin Liver Dis 1995; 15: 123-132.
17. Porayko MK, Textor SC, Krom RAF, et al. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc 1994; 69: 105-111.
18. Bilbao I, Charco R, Balsells J, et al. Risk factors for acute renal failure requiring dialysis after liver transplantation. Clin Transplant 1998; 12: 123-129.
19. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59: 361-365.
20. Fisher NC, Nightingale PG, Gunson BK, Lipkin G, Neuberger JM. Chronic renal failure following liver transplantation. A retrospective analysis. Transplantation 1998; 66: 59-66.
21. Singh N, Gayowski T, Marino IR. Haemolytic uremic syndrome in solid-organ transplant recipients. Transpl Int 1996; 9: 68-75.
22. Sandborn WJ, Hay JE, Porayko MK, et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994; 19: 925-932.
23. Chan C-Y, DasGupta, Baker AL. Cyclosporine A: drug discontinuation for the management of long-term toxicity after liver transplantation. Hepatology 1996; 24: 1085-1089.
24. Devlin J, Slapak G, Portmann B, Williams R. Immunosuppression withdrawal in long-term liver transplant recipients. Hepatology 1994; 20: 124A
25. Grinyó JM. Progress with cyclosporine-sparing regimens. Transplant Proc. 1999; 31(suppl 8A): 11S-16S.
26. Eckhoff DE, McGuire BM, Frenette LR, et al. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998; 65: 180-187.
27. Watson CJE, Friend PJ, Jamieson NV, et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999; 67: 505-509.
28. Papatheodoridis GV, O'Beirne, Mistry P, et al. Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment. A preliminary report. Transplantation 1999; 68: 155-157.